Sana Biotechnology
SANA
120 hedge funds and large institutions have $427M invested in Sana Biotechnology in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 34 reducing their positions, and 13 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 34
1.05% more ownership
Funds ownership: 67.26% → 68.31% (+1%)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
1% more funds holding
Funds holding: 119 → 120 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less capital invested
Capital invested by funds: $507M → $427M (-$79.3M)
56% less call options, than puts
Call options by funds: $14K | Put options by funds: $32K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$8.45M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$7.99M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.95M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.37M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$4.38M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$4.01M |
| 3 |
Goldman Sachs
New York
|
-$3.55M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.03M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$715K |
SANA Hedge Fund Activity: Q1 2023 in Review
120 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q1 2023, worth a combined $427M — down 16% from $507M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SANA positions and 13 closed out — a net gain of 1 holder — while 41 added to existing stakes and 34 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $8.45M. The largest seller was State Street, cutting an estimated $4.38M.
- 120 institutional investors held Sana Biotechnology (SANA) as of Q1 2023, up from 119 in Q4 2022.
- Funds reported $427M of Sana Biotechnology stock for Q1 2023, down 16% quarter-over-quarter.
- 14 funds opened new Sana Biotechnology positions in Q1 2023 and 13 closed out, a net change of +1 holder.
- The largest Sana Biotechnology buyer in Q1 2023 was Suvretta Capital Management, an estimated $8.45M added.
- The largest Sana Biotechnology seller in Q1 2023 was State Street, an estimated $4.38M sold.
Based on aggregated 13F filings for Q1 2023.